Rolofylline is being developed for the treatment of acute congestive heart failure and renal impairment; it can alleviate presynaptic dysfunction, restore neuronal activity and dendritic spine levels in vitro, and may be used to counteract hypometabolism and neurological dysfunction associated with tau-induced neurodegenerative diseases.